Explore the latest in adverse drug events, including postmarketing surveillance, risk mitigation, and the pharmacogenetics of safety.
This Viewpoint analyzes data on the thrombotic risk associated with cyclin-dependent kinase inhibitors and notes the need for additional research on the thrombotic risk of these drugs, the influence of combined drug therapy on thrombotic risk, and patient selection.
This study examines the FDA Adverse Event Reporting System and PubMed databases for cases of noninfectious pneumonia acquired after FDA approval of the drug ustekinumab.
This cohort study assesses self-reported quality of life among patients referred to oncodermatology clinics for pruritus associated with immunotherapy.
This cohort study of Tennessee Medicaid enrollees from 1999 through 2014 investigates the risk of unexpected death among children and youths aged 5 through 24 years without psychosis who are new users of antipsychotic medications compared with new users of control medications.
This systematic review and meta-analysis examines randomized clinical trials (RCTs) of modern cancer drugs in the adjuvant setting to determine the incidence of severe adverse events reported in placebo groups.
This secondary analysis of a randomized clinical trial examines the association of modern chemoradiotherapy with survival among patients with stage I to II small cell lung cancer compared with that among patients with stage III small cell lung cancer.
This case report describes cyclosporine-induced gingival hypertrophy in a child with aplastic anemia.
This retrospective observational analysis of health claims data compares the safety, effectiveness, and cost of biosimilar filgrastim and filgrastim.
This cohort study of female participants with stage 0 to IIA breast cancer treated with breast-conserving surgery and whole-breast irradiation assesses whether radiation-induced toxicities of normal breast tissue 3 years after radiotherapy are associated with the transforming growth factor β gene variant C−509T.
This population-based cohort study evaluates the incidence of acute endophthalmitis after intravitreal injections of corticosteroids or anti–vascular endothelial growth factor agents in a nationwide French registry.
This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment.
This systematic review summarizes evidence on the effectiveness and safety of current cryotherapy methods to prevent hair, skin, and nail changes associated with chemotherapy.
This medical record review evaluates the efficacy and safety of dapsone as second-line therapy in patients with chronic spontaneous urticaria.
This case study investigates the possible association of tumor necrosis factor α inhibitor treatment with adverse ophthalmologic events, in this case blepharitis and ectropion.
This cohort study examines the association of screening for hypogammaglobulinemia with the risk of infection and mortality in patients who received rituximab therapy.
This cross-sectional study uses a serum-based liquid chromatography–tandem mass spectrometry assay to measure drug concentrations of medications in blood samples to assess the accuracy of medical records and patient adherence.
This cohort study evaluated associations of increased creatinine levels, hyperkalemia, and continuation of therapy with the risk of emergency department visits, hospitalizations, and mortality within 1 year after initiation of renin angiotensin aldosterone system inhibitor (RAASI) therapy in patients with chronic kidney disease.
The case report describes the occurrence of antiphospholipid syndrome following pembrolizumab treatment of stage IIIB unresectable melanoma.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: